

Nanoscale Advances

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: S. Umapathy and I. Pan, *Nanoscale Adv.*, 2025, DOI: 10.1039/D4NA00644E.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.

1 **Title: Glucose Reduced Nano-Se Mitigate Cu-Induced ROS by Upregulating**
2 **Antioxidant Gene in Zebrafish Larvae**

3
4 **Author Name:** Suganiya Umapathy and Ieshita Pan*

5
6 **Address:** Institute of Biotechnology, Department of Medical Biotechnology, Saveetha
7 School of Engineering, Saveetha Institute of Medical and Technical Sciences, Thandalam,
8 Chennai, 602 105, Tamil Nadu, India

9
10 ***Correspondence:** bony.iesk@gmail.com; ieshitapan.sse@saveetha.com

11
12
13
14 **Keywords:** Oxidative Stress, Nano-Se, Zebrafish Model, Antioxidant, Cognitive,
15 Neurodegenerative Diseases

16
17
18
19



20 ABSTRACT

View Article Online
DOI: 10.1039/D4NA00644E

21 This study compares the therapeutic efficiency of bovine serum albumin-stabilized
22 selenium nanoparticles in reducing oxidative stress and improving cellular health. The
23 nanoparticles were synthesized using mussel-extracted selenium with two reducing agents:
24 D-glucose and orange. Inductively coupled plasma-optical emission spectroscopy and X-ray
25 Diffraction analyses confirmed the presence of selenium. The reducing agent and duration
26 influenced the nanoparticle size. Reduction with D-glucose for 1 hour revealed that the
27 particles exhibited an average size of 10 nm. Copper sulphate-induced malformations like
28 yolk sac and pericardial edema were observed with 25 $\mu\text{g/ml}$ of orange-reduced
29 nanoparticles, while D-glucose-reduced nanoparticles mitigated these malformations at 25
30 $\mu\text{g/ml}$. Treatment with stabilized Se-NPs reduced with D-glucose for 30 minutes showed
31 33% dose-dependent radical scavenging activities, upregulated approximately 2-fold of
32 superoxide dismutase, catalase, glutathione reductase, and glutathione peroxidase encoding
33 genes, restored homeostasis by decreasing lipid peroxidation (27.32 nmol/mg/ml) and nitric
34 oxide levels (6.71 μM). They also had the potential to restore cognitive properties like larval
35 movement (93.40 m) without altering larval behaviour. Live cell imaging indicated a
36 significant decrease in cellular reactive oxygen species and lipid peroxidation levels in the
37 gut and liver. These findings suggest that Se-NPs reduced for 30 minutes with D-glucose are
38 promising candidates for oxidative stress-induced neurodegeneration.

39 INTRODUCTION

40 Mitochondria are dynamic, membrane-bound organelles that play a pivotal role in
41 orchestrating cellular energy production in almost all eukaryotic cells. They are central to
42 sustaining life by generating the ATP required for various cellular functions and regulating
43 several metabolic processes, including redox homeostasis, calcium signaling, and cellular
44 apoptosis^{1,2}. Mitochondria are one of the most crucial organelles involved in the structure and
45 function of neuronal networks in the brain. Disruption of mitochondrial homeostasis can
46 directly progress oxidative damage, leading to neurodegeneration³. Major contributors to
47 mitochondrial dysfunction are mitochondrial fission, fusion, and mitophagy, leading to
48 neurodegenerative diseases including Alzheimer's Disease (AD), Parkinson's Disease (PD),
49 Amyotrophic Lateral Sclerosis (ALS), and Prion diseases etc^{4,5}. Excessive fusion leads to the
50 formation of elongated mitochondrial tubules, while increased fission initiates the
51 fragmentation of mitochondria⁶. These events trigger oxidative stress, halt the production of
52 energy, and cause abnormal signaling in cellular pathways⁷. Reactive oxygen species (ROS)
53 can be both beneficial and detrimental to human health. Generally, ROS contributes to
54 several redox-regulating processes within cells to maintain cellular homeostasis. However,
55 overproduction and accumulation of ROS lead to oxidative stress, damaging cell structures
56 and causing various diseases^{8,9}. Under both healthy and pathological situations, mitochondria
57 are the primary source of ROS. Superoxide and hydroxyl radicals are the primary oxygen-
58 free radicals¹⁰. Cellular respiration like lipoxygenases (LOX) and cyclooxygenases (COX),
59 produces superoxide anion radicals¹¹. The pathophysiology of chronic illnesses like cancer,
60 diabetes, neurodegenerative diseases, and cardiovascular diseases is heavily influenced by
61 oxidative stress. Oxidative stress increases the levels of pro-oxidant factors, leading to
62 structural alterations in mitochondrial DNA and functional alterations by aberrant gene
63 expression¹².

64 Nanotechnology has received significant attention due to the well-established fact that
65 its combination with biotechnology creates a platform with enormous potential and
66 significance in terms of its variety of applications¹³. Different kinds of nanoparticles (NPs)



67 can be formulated to maximize their functions; these include semiconductor, metal, metal
68 oxide, organic, and inorganic NPs. Semiconductor nanoparticles, such as quantum dots, are
69 used in controlled drug release due to their responsive optical and electronic properties¹⁴.
70 Treatment with metal oxide NP i.e., CeO₂-NP decreased post-injury neuronal death
71 and damage while improving CAT, SOD activity levels, and glutathione:glutathione-disulfide
72 ratios notably¹⁵. Silver NP efficiently inhibited lipid peroxidation (LPO) by scavenging ROS,
73 showing their antioxidant effectiveness¹⁶. Organic NPs, such as liposomes, enhance drug
74 bioavailability by encapsulating hydrophobic drugs¹⁷, while inorganic NPs offer stability and
75 targeted delivery¹⁸. Diverse approaches can be implemented in the production of NPs,
76 including green synthesis and conventional chemical synthesis¹⁹. Selenium (Se) is an
77 essential micronutrient that is involved in the proper functioning of all organisms. It is a
78 cofactor of many enzymes including glutathione peroxidase and thioredoxin reductase.
79 Selenoproteins, such as selenocysteine and selenomethionine are crucial forms naturally
80 present in prokaryotes and eukaryotes. Se is an effective radical scavenging agent against
81 oxidative stress²⁰. Deficiency of Se can lead to chronic diseases such as diabetes,
82 cardiovascular disease, obesity, respiratory diseases, neurodegenerative diseases, and cancer
83 ²¹. To overcome this, inorganic forms of Se (selenite and selenate) are being used as dietary
84 supplementation²⁰. Selenium nanoparticles (Se-NPs) are known to have high bioavailability
85 and a low toxicity profile^{22–24}. They can reduce the accumulation of free radicals and prevent
86 oxidative stress²⁵. One of the major contributors to free radicals is an increase in NO and
87 malondialdehyde (MDA) levels, which triggers LPO^{26,27}. Copper NP triggers oxidative stress
88 by elevating LPO while disrupting antioxidant enzymes²⁸. Se-NPs significantly reduce MDA
89 levels and restore antioxidant enzyme activity^{29,30}. Se-NPs potentially eliminated oxidative
90 stress induced by streptozotocin by decreasing the LPO and NO levels in the
91 pancreas³¹. Therefore, nano-Se plays a crucial role as an antioxidant defence
92 system³². Moreover, Se-NPs can cross the blood-brain barriers showing their potential in
93 modulating inflammation and brain-related diseases^{33,34}. Some of the emerging *in vitro* and *in*
94 *vivo* studies using PC12 cell lines and rat model highlighted the therapeutic efficacy of Se-
95 NPs in mitigating oxidative stress and neurodegenerative diseases such as AD and PD^{35–38}.
96 Though Se-NPs have many therapeutic benefits, most were chemically synthesized using
97 sodium selenite which may induce mild toxic effects^{39–42}.

98 This study hypothesizes that Se-NPs could mitigate copper-induced neurotoxicity
99 through multiple mechanisms, including reducing oxidative stress, restoring mitochondrial
100 function, and reactivating antioxidant enzyme systems. Copper-induced toxicity is known to
101 generate excessive reactive oxygen species (ROS), leading to lipid peroxidation,
102 mitochondrial dysfunction, and inhibition of key enzymes such as SOD, CAT, GSH, GPx,
103 and AChE. By counteracting these effects, Se-NPs hold promise as a therapeutic strategy for
104 addressing oxidative stress-related neurodegenerative conditions. In this study, we
105 synthesized Se-NPs using selenium obtained from mussels. Mussels are known for their
106 unique ability to bioaccumulate selenium, a micronutrient with potential antioxidant and
107 health benefits. We employed various reducing agents, namely D-glucose and orange with
108 BSA as a stabilizer. These reducing agents were applied at two different time intervals to
109 assess their efficiency in reducing the size and preventing aggregation of the nanoparticles.
110 The synthesized Se-NPs were characterized and subsequently tested for their antioxidant and
111 neuroprotective properties against copper sulfate (CuSO₄)-induced stress *in vivo* in zebrafish
112 larvae. The study aims to evaluate the potential of Se-NPs in restoring enzymatic activity and
113 neurotransmitter function disrupted by copper toxicity while highlighting their broader
114 applications in mitigating oxidative stress-induced damage.


115

116 RESULTS AND DISCUSSION




117 **Synthesis and Characterization of Mussels Extracted Se**View Article Online
DOI: 10.1039/D4NA00644E

118 Different extraction methods such as 0.8% saline and Tris-HCl buffer (pH-
119 7.4) extraction methods were utilized to determine the most suitable method for extracting Se
120 from mussels. Results from ICP-OES showed sharp peak at 196.03 nm with a concentration
121 of 0.93 mg/L for the saline extraction method and 0.51 mg/L for the buffer extraction method
122 (**Fig. 1a,b**). Similarly, a study conducted by Tyburska *et al.* also reported a peak at 196.03
123 for selenium⁴³. For Se extracted using a saline method, the XRD data revealed peaks at
124 26.51°, 31.58°, 45.33°, 56.31°, 66.13°, and 75.16° angles corresponding to the planes (100),
125 (110), (111), (112), (210), and (113), respectively. The nature was observed to be 85%
126 crystalline and 15% amorphous. Conversely, Se extracted using the buffer method showed
127 peaks at 22.16° and 26.77°, corresponding to the planes (100) and (110), respectively (**Fig.**
128 **1c,d**). The nature was observed to be 70% crystalline and 30% amorphous. A study conducted
129 in 2019, by Hassanien *et al.* focused on dye degradation and also observed XRD peaks
130 aligning with the corresponding planes for Se-NPs confirming the presence of Se⁴⁴.



131

132 **Fig. 1 Synthesis and Characterization of Se extracted from mussel and Se-NPs:** ICP-OES(a) Saline
133 extracted Se; (b) Buffer extracted Se; XRD analysis (c) Saline extracted Se; (d) Buffer extracted Se; SEM (e-f)
134 stabilized Se-NPs reduced for 30 minutes and 1 hour with D-glucose; (g-h) stabilized Se-NPs reduced for 30
135 minutes and 1 hour with orange; TEM and SAED (i-j) stabilized Se-NPs reduced for 30 minutes with D-




136 Glucose;(k-l) stabilized Se-NPs reduced for 30 minutes with orange. Yield (m) Percentage of Se yield. FTIR (n)
137 stabilized Se-NPs reduced for 30 minutes and 1 hour with D-glucose; (o) stabilized Se-NPs reduced for 30
138 minutes and 1 hour with orange peel extract.

139 Synthesis and Characterization of Mussel extracted Se-NPs

140 Se was reduced using D-glucose and orange peel extract to synthesize Se-NPs. The
141 reduction process was carried out at two different time periods (30 minutes and 1 hour) to
142 determine the efficiency of reducing agents and were stabilized using BSA to prevent
143 aggregation. A study by El Badawy *et al.* reported that stabilization kinetics impact the
144 aggregation pattern of nanoparticles⁴⁵. SEM imaging at 5×10^{-3} magnification was done to
145 determine the morphology of Se-NPs. SEM results showed that the nanoparticles revealed a
146 near-spherical shape for both non-stabilized and stabilized Se-NPs. Compared to non-
147 stabilized Se-NPs, stabilized nanoparticles exhibited less aggregation. The mean area and
148 length of the nanoparticles were calculated using ImageJ software, which was found to be
149 20 ± 3 and 10 ± 3 nm for stabilized Se-NPs reduced with D-glucose for 30 minutes and 1 hour
150 (**Fig. 1e,f**). On the contrary, the size of non-stabilized Se-NPs reduced with orange for 30
151 minutes and 1 hour was observed to be 33 ± 6 and 29 ± 7 nm (**Supplementary Fig 1a,b**). In
152 2016, a study by Nie *et al.* on the synthesis of highly uniform Se-NPs using glucose as a
153 reductant reported that the nanoparticles were spherical and were about 240 nm in
154 size⁴⁶. Glucose-reduced Se-NPs were spherical with a size ranging from 280-295 nm⁴⁶. Se-
155 NPs reduced with orange were reported to be spherical with a size range of 16–95
156 nm⁴⁷. Similarly, the size of stabilized Se-NPs reduced with orange peel extract for 30 minutes
157 and 1 hour was observed to be 19 ± 4 and 18 ± 7 nm (**Fig. 1g,h**), respectively, while non-
158 stabilized Se-NPs reduced with orange peel extract for 30 minutes and 1 hour were found to
159 be 29 ± 8 and 26 ± 9 nm (**Supplementary Fig 1c,d**), respectively. A study on the green
160 synthesis of Se-NPs using orange peel by Salem *et al.* reported that the nanoparticles were
161 spherical and size ranged between 16-95 nm⁴⁷. Se-NPs synthesized from mussel-extracted Se
162 were found to be similar in shape and were reduced better with D-glucose. Based on the size
163 reduction and aggregate formation it was assumed that the stabilized reduction process
164 produced better nanoparticles which can be an advantage to pass through the blood-brain
165 barrier. TEM imaging confirms the near-spherical shape. The mean area of Se-NPs reduced
166 with D-glucose was 23.95 ± 6.18 nm (**Fig. 1i**) and Se-NPs reduced with orange was
167 53.50 ± 21.96 nm (**Fig. 1k**). A study by Van der Horst *et al.* on electrochemical sensor
168 applications using bismuth-silver nanoparticles showed that TEM of silver nanoparticles
169 ranged between 10 and 20 nm with spherical shapes and accompanied with some
170 aggregates⁴⁸. SAED pattern showed concentric diffraction rings interspersed with discrete
171 spots, which are characteristic of a polycrystalline material with localized crystalline
172 domains. This indicates that the sample contains multiple crystallites with varying
173 orientations, contributing to the ring formation (**Fig. 1j&l**). Particle size analysis showed that
174 Se-NPs reduced with D-glucose and orange were monodispersed with a size of 310.1 ± 73.2
175 nm and 378 ± 102.1 nm under refractive index 1.59 (**Supplementary Fig 1e**). Zeta potential
176 was measured at -1.2 mV and 0.4 mV, indicating the particles have a very low surface charge
177 or are nearly neutral, which tend to aggregate. The sharp peak implies a uniform distribution
178 of zeta potential values (**Supplementary Fig 1f,g**). Similar patterns were observed in a study
179 by Bhattacharyya *et al.* on the one-pot fabrication of silver nanoparticles⁴⁹.

180 The total yield of Se was observed to be approximately 10% higher in the 0.8% saline
181 extraction method, compared to the buffer extraction method (**Fig. 1m**). This percentage was
182 calculated based on the dry weight of the extracted selenium in milligrams. The chemical
183 attributes of the stabilized Se-NPs were determined using FTIR. The smooth and sharp peaks




184 observed were at 3276.55-3278.35 cm^{-1} (medium, sharp C-H stretching alkene), 2920.69
185 2850.78 cm^{-1} (medium, sharp C-H stretching alkane), 1626.11-1626.07 cm^{-1} (medium, C=C
186 stretching di-substituted alkene), 1531.68-1530.69 cm^{-1} (strong, N-O stretching nitro-
187 compound), 1404.61-1402.19 cm^{-1} (strong, S=O stretching sulfonyl chloride), 1228.67-
188 1228.37 cm^{-1} (strong, C-O stretching alkyl aryl ether), 1038-1035.12 cm^{-1} (strong, S=O
189 stretching sulfoxide), and 518.39-404.31 cm^{-1} (strong, metal-ligand stretching) for stabilized
190 Se-NPs reduced for 30 minutes and 1 hour with D-glucose (**Fig. 1n**). Stabilized Se-NPs
191 reduced for 30 minutes and 1 hour with orange showed peaks at 3278.91-3273.23 cm^{-1}
192 cm^{-1} (medium, sharp C-H stretching alkene), 2924.34-2851.30 cm^{-1} (medium, sharp C-H stretching
193 alkane), 1627.70-1627.66 cm^{-1} (medium, C=C stretching di-substituted alkene), 1532.01-
194 1515.51 cm^{-1} (strong, N-O stretching nitro-compound), 1404.68-1392.67 cm^{-1} (strong, S=O
195 stretching sulfonyl chloride), 1236.15-1228.28 cm^{-1} (strong, C-O stretching alkyl aryl ether),
196 1033.83-1031.98 cm^{-1} (strong, S=O stretching sulfoxide), and 472.40-410.13 cm^{-1} (strong,
197 metal-ligand stretching)(**Fig. 1o**). The obtained peaks indicated the presence of metal,
198 stabilizer, and the reducing agents used (**Supplementary Table 1**). The time of reduction and
199 variation in the reducing agent did not significantly affect the position of functional groups in
200 the nano-Se. Similar peaks were observed in the study reported by Alagesan & Venugopal for
201 green-synthesized Se-NPs⁵⁰.

202 Developmental Toxicity Assessment

203 The developmental toxicity assessment of Se-NPs (5-25 $\mu\text{g}/\text{ml}$) was conducted using
204 zebrafish embryos. Concentration was selected based on a previously reported study that
205 obtained a similar model and showed regulated biological effects without exacerbating the
206 system⁵¹. In the control group, no abnormal morphological changes were observed. Groups
207 treated with stabilized Se-NPs reduced with D-glucose for 30 minutes and 1 hour (5-
208 25 $\mu\text{g}/\text{ml}$) for 0-72 hpf showed no malformation, compared to the stress-exposed group which
209 showed malformations like pericardial edema (PSE) and yolk sac edema (YSE)(**Fig. 2a,b**).
210 On the other hand, groups treated with stabilized Se-NPs(5-20 $\mu\text{g}/\text{ml}$)reduced with orange for
211 30 minutes and 1 hour showed no malformations, while 25 $\mu\text{g}/\text{ml}$ showed malformations like
212 bent spine (BS) and YSE (**Fig. 2c,d**). Compared to stabilized Se-NPs reduced with orange for
213 30 minutes and 1 hour, stabilized nano-Se reduced with D-glucose for 30 minutes and 1 hour
214 showed a higher survival rate at 96 hpf, reducing CuSO_4 -induced stress (**Fig. 2a1-d1**). Bulk
215 selenium showed lesser survival rate compared to nano-selenium (**Supplementary Fig 2**). A
216 previous study on green synthesized Se-NPs and their toxicity profile by Kalishwaralal *et al.*
217 reported that at 15-25 $\mu\text{g}/\text{ml}$, malformations like tail malformation and PSE were
218 observed⁵¹. Exposure to hydrogen peroxide (5 mM) until 120 hours post-fertilization induced
219 stress, significantly reducing the survival rate of zebrafish embryos and
220 larvae⁵². Furthermore, zebrafish embryos and larvae treated with BSA-synthesized Se-NPs at
221 concentrations of 20-25 $\mu\text{g}/\text{ml}$ showed mortality⁵¹. Therefore, mussel-extracted Se-NPs
222 reduced with glucose can be a potential alternative source with lower toxicities.






223 **Fig.2** *In Vivo* Developmental Toxicity Analysis in zebrafish embryos and larvae representing, Control
 224 group; Stress group (CuSO₄-induced stress); and Stabilized Se-NPs (5-25 µg/ml) treatment group. (a-b)
 225 stabilized Se-NPs reduced with D-glucose for 30 minutes and 1 hour, (c-d) stabilized Se-NPs reduced with
 226 orange peel extract for 30 minutes and 1 hour. Survival rate (a1-b1) stabilized Se-NPs reduced with D-glucose for
 227 30 minutes and 1 hour, (c1-d1) stabilized Se-NPs reduced with orange peel extract for 30 minutes and 1 hour. The
 228 data were considered significant (p < 0.05) and marked by the symbol “*”.

229 *In Vitro* Antioxidant Analysis of Stabilized Se-NPs

230 a) DPPH Scavenging Assay

231 The DPPH scavenging assay was conducted to evaluate the ROS scavenging activity.
 232 As a positive control, ascorbic acid (AsA) exhibited 50% scavenging activity. Stabilized Se-
 233 NPs reduced with D-glucose for 30 minutes and 1 hour showed concentration-dependent
 234 DPPH scavenging activity. The highest scavenging activity was observed at a concentration
 235 of 25 µg/ml with 33.20% and 29.29% inhibition (Fig. 3a,b). Stabilized Se-NPs reduced with
 236 orange peel extract for 30 minutes and 1 hour, exhibited radical scavenging activity at all
 237 concentrations, but the highest activity was seen at a concentration of 15 µg/ml with 18.62%
 238 inhibition. Additionally, the stabilized nano-Se reduced with orange peel extract for 1 hour
 239 showed 17.79% radical scavenging activity (p < 0.05) (Fig. 3c,d). The IC₅₀ value was
 240 observed to be 20.59 µg/ml. Therefore, stabilized Se-NPs were found to be efficient DPPH
 241 scavengers. In a 2017 study reported by Vyas & Rana, it was shown that aloe extract
 242 combined with Se-NPs had higher DPPH scavenging activity than aloe extract alone⁵³,
 243 indicating the significant potential of Se-NPs as an antioxidant. Conversely, a study by Zhai *et al.*
 244 reported that chitosan-reduced Se-NPs exhibited ~60% higher scavenging activity in the
 245 ABTS assay compared to the DPPH assay⁵⁴.





246

247 **Fig. 3 In Vitro Antioxidant Activity:** DPPH assay of (a-b) stabilized Se-NPs reduced with D-glucose for 30
 248 minutes and 1 hour, (c-d) stabilized Se-NPs reduced with orange peel extract for 30 minutes and 1 hour. ABTS
 249 assay of (e-f) stabilized Se-NPs reduced with D-glucose for 30 minutes and 1 hour, (g-h) stabilized Se-NPs
 250 reduced with orange peel extract for 30 minutes and 1 hour. The data were considered significant ($p < 0.05$) and
 251 marked by the symbol “*”.

252 b) ABTS Scavenging Assay

253 The ABTS scavenging assay was conducted to determine the ROS scavenging
 254 activity. Ascorbic acid (AsA) exhibited 55% scavenging activity, serving as a positive control.
 255 All stabilized Se-NPs reduced with D-glucose displayed concentration-dependent scavenging
 256 activity. However, the maximum activity was observed at 30 minutes and 1 hour, with
 257 percentages of 32.59% and 30.01% respectively, at a concentration of 25 $\mu\text{g/ml}$ (Fig. 3e,f). In
 258 another group, stabilized Se-NPs reduced with orange peel extract for 30 minutes and 1 hour,
 259 showed radical scavenging activity across all concentrations. The maximum inhibition was
 260 observed at a concentration of 15 $\mu\text{g/ml}$ ($p < 0.05$), for both 30 minutes (21.25%) and 1 hour
 261 (19.84%) (Fig. 3g,h). The IC₅₀ value corresponds to 16.86 $\mu\text{g/ml}$, respectively. Vyas & Rana
 262 also noted that aloe extract combined with Se-NPs exhibited higher ABTS scavenging activity
 263 compared to aloe extract alone⁵³, suggesting their potential antioxidant properties.

264 In Vivo Enzymatic Assay of Stabilized Se-NPs

265 a) SOD Assay

266 SOD levels were determined using a homogenized sample of zebrafish larvae exposed
 267 to CuSO₄ followed by treatment with stabilized Se-NPs. In the CuSO₄ exposed group, SOD
 268 levels drastically decreased to 7.33 U/mg of protein (a 57% reduction), compared to the
 269 control (16.90 U/mg of protein). Stabilized Se-NPs reduced with D-glucose for 30 minutes
 270 and 1 hour, restored the enzyme levels by more than 83%, producing SOD levels of 14.74
 271 U/mg of protein and 14.11 U/mg of protein respectively at a concentration of 25 $\mu\text{g/ml}$,
 272 showing a concentration-dependent enhancement in enzyme activity (Fig. 4a,b).
 273 Alternatively, at 15 $\mu\text{g/ml}$ concentration, stabilized Se-NPs reduced with orange for 30
 274 minutes and 1 hour showed total SOD levels of 12.15 U/mg of protein and 11.84 U/mg of
 275 protein, approximately 72% and 70% restoration compared to the control. However, at a
 276 concentration of 25 $\mu\text{g/ml}$, the pattern was reversed with a decrease in SOD activity to 10.24
 277 U/mg of protein and 9.90 U/mg of protein (Supplementary Fig 3a,b), respectively. In 2023,
 278 a study by Naz *et al.* showed that CuSO₄ decreased SOD levels⁵⁵. However, Khan *et al.* in
 279 2022 reported that SOD enzyme levels can be elevated upon Se-NPs application⁵⁶.



280 b) CAT Assay

281 CAT levels were assessed using a standardized sample of zebrafish larvae exposed to
282 CuSO₄ followed by treatment with stabilized Se-NPs. In the group exposed to CuSO₄, there
283 was a significant decrease in CAT levels specifically 2.49 μmol/mg of protein, compared to
284 the control group (8.72 μmol/mg of protein). Zebrafish larvae exposed to CuSO₄ and treated
285 with stabilized Se-NPs combined with D-glucose for 30 minutes and 1 hour exhibited a dose-
286 dependent increase in total CAT levels of 7.33 μmol/mg and 7.16 μmol/mg of protein at a
287 concentration of 25 μg/ml (**Fig. 4c,d**). While treated with 15 μg/ml stabilized Se-NPs reduced
288 with orange for 30 minutes and 1 hour, the total CAT concentration only increased to
289 5.64 μmol/mg and 5.67 μmol/mg respectively. However, at a concentration of 25 μg/ml, CAT
290 activity decreased to 4.59 μmol/mg and 4.55 μmol/mg of protein (**Supplementary Fig 3c,d**),
291 respectively. In 2023, Sariñana-Navarrete *et al.* stated that Se-NPs are effective antioxidants
292 and maintain redox signaling by increasing the levels of the CAT enzyme⁵⁷.


293 c) Lipid Peroxidation Assays

294 In the CuSO₄ exposed stress group, significantly higher levels of MDA at 81.69
295 nmol/mg/ml were observed compared to the control group (17.09 nmol/mg/ml). When
296 treating zebrafish larvae exposed to CuSO₄, stabilized Se-NPs reduced with D-glucose for 30
297 minutes and 1 hour at a concentration of 25 μg/ml significantly decreased the MDA levels by
298 27.32 and 33.84 nmol/mg/ml respectively (**Fig. 4e,f**). Conversely, treatment with 15 μg/ml of
299 stabilized Se-NPs reduced with orange peel extract for 30 minutes and 1 hour also reduced
300 MDA levels by approximately 38% and 33% compared to the CuSO₄ exposed stress group
301 (**Supplementary Fig 3e,f**). Liu *et al.* emphasized that copper nanoparticles induce oxidative
302 stress by increasing LPO while disrupting SOD, CAT, and GPx enzyme activity²⁸. A study
303 by Lesnichaya *et al.* on carbon tetrachloride-induced toxicity in the liver reported that nano-Se
304 neutralized the LPO levels⁵⁸.

305 d) Estimation of NO levels

306 NO levels were determined using the Griess reagent assay. CuSO₄-exposed zebrafish
307 larvae showed a 1.98 times enhancement of NO levels (12.9 μM) compared to the control
308 group (6.49 μM). Treatment with 25 μg/ml stabilized Se-NPs reduced with D-glucose for 30
309 minutes and 1 hour, resulted in a dose-dependent decrease in NO levels with approximately
310 6.71 μM and 7.02 μM measured for the 30 minute and 1 hour treated groups, respectively
311 (**Fig. 4g,h**). Conversely, for CuSO₄ exposed-zebrafish larvae treated with 15 μg/ml of
312 stabilized Se-NPs reduced with orange peel extract for 30 minutes and 1 hour, the measured
313 NO levels were 8.87 μM and 9.68 μM (**Supplementary Fig 3g,h**), respectively. Though both
314 nanoparticles were effective in restoring NO levels upon treatment, stabilized Se-NPs
315 reduced with D-glucose were found to be more efficient compared to orange-reduced nano-
316 Se. A study by Anuse *et al.*, reported that Se-NPs significantly reduced NO levels⁵⁹.






317 **Fig. 4 In Vivo Antioxidant Activity of stabilized Se-NPs:** SOD assay (a-b) reduced with D-glucose for 30
 318 minutes and 1 hour, CAT assay (c-d) reduced with D-glucose for 30 minutes and 1 hour. LPO assay (e-f)
 319 reduced with D-glucose for 30 minutes and 1 hour. NO assay (g-h) reduced with D-glucose for 30 minutes and 1
 320 hour. GSH assay (i-j) reduced with D-glucose for 30 minutes and 1 hour. GST assay (k-l) reduced with D-glucose
 321 for 30 minutes and 1 hour. RT-PCR (m) reduced with D-glucose for 30 minutes (25 µg/ml). The data were
 322 considered significant ($p < 0.05$) and marked by the symbol “*”.

323 e) Estimation of GSH activity

324 The group exposed to CuSO₄ showed a significant reduction in GSH activity (4.67
 325 nmol/mg protein) compared to the control group (7.89 nmol/mg protein). However, treatment
 326 with 25 µg/ml of stabilized nano-Se reduced with D-glucose for 30 minutes and 1 hour
 327 significantly increased GSH activity in CuSO₄-exposed zebrafish larvae. The GSH
 328 levels increased to 7.02 and 6.49 nmol/mg of protein, respectively (**Fig. 4i,j**). A similar effect
 329 was observed when using stabilized Se-NPs reduced with orange peel extract at a
 330 concentration of 15 µg/ml for 30 minutes and 1 hour. However, the GSH activity only
 331 increased to 6.17 and 5.72 nmol/mg of protein (**Supplementary Fig 3i,j**). Therefore,
 332 stabilized nano-Se has potential antioxidant properties, which can reduce oxidative stress and
 333 protect cellular homeostasis. El-Borady *et al.* reported that Se-NPs increased GSH levels by
 334 decreasing ROS levels⁶⁰.

335 f) Estimation of GST activity

336 The CuSO₄ exposed group showed a significant reduction in GST activity (4.04 U/mg
 337 protein) compared to the control group (8.59 U/mg protein). Treatment with 25 µg/ml of
 338 stabilized Se-NPs reduced with D-glucose for 30 minutes and 1 hour significantly increased
 339 GST activity to approximately 8.23 and 8.06 U/mg of protein respectively (**Fig. 4k,l**).
 340 However, treatment with a concentration of 15 µg/ml of stabilized Se-NPs reduced with



341 orange peel extract for 30 minutes and 1 hour only restored GST activity up to 7.59 and 7.55
342 U/mg of protein (**Supplementary Fig 3k,l**). This indicates the potential of stabilized Se-NPs
343 to reduce oxidative stress. Horky *et al.* study on the antioxidant activity of Se showed an
344 improvement in GST activity by 25.3%⁶¹.


345 **Expression of Antioxidant Genes**

346 Deficiency of selenium, a key component of antioxidant enzymes, modulates
347 selenoproteins in turn triggering ROS production, leading to disruption of cellular
348 homeostasis^{62,63}. An antioxidant gene expression study was conducted in zebrafish larvae
349 exposed to CuSO₄ and treated with stabilized Se-NPs reduced for 30 minutes and 1 hour with
350 D-glucose as well as orange peel extract. Compared to the control group, the CuSO₄-induced
351 stress group showed significant downregulation of SOD (0.2-fold), CAT (0.1-fold),
352 glutathione-disulfide reductase (GSR) (0.1-fold), and Glutathione peroxidase (GPX) (0.4-
353 fold) expression. In contrast, treatment with stabilized Se-NPs reduced for 30 minutes and 1
354 hour with D-glucose and stabilized Se-NPs reduced for 30 minutes and 1 hour with orange
355 peel extract significantly ($p < 0.05$) upregulated the SOD (2.2-fold), CAT (1.7-fold), GSR
356 (2.1-fold), and GPX (2.5-fold) expression, confirming its potential in influencing the
357 expression of antioxidant genes by mitigating ROS (**Fig. 4m**). This protective effect may
358 likely be mediated through the nuclear factor erythroid 2-related factor 2 (NRF-2)
359 pathway^{64,65}. NRF-2 is a transcription factor that plays a pivotal role in cellular defense
360 against oxidative stress. Under oxidative stress conditions, NRF-2 dissociates from Keap1
361 and binds to antioxidant response elements⁶⁶. Real-time PCR studies reported by Handa *et al.*
362 showed that upon utilization of selenium anti-oxidative enzymes encoding gene expression
363 were elevated⁶⁷.

364 **Localization of Cellular ROS**

365 To evaluate the intracellular ROS level, DCFDA fluorescent staining was
366 performed on zebrafish larvae (96 hours post fertilization; 96 hpf). The control group showed
367 a mean fluorescent intensity (MFI) of 8.9. Zebrafish larvae exposed to CuSO₄ had ROS levels
368 of 61.75 MFI. While overall cellular ROS was detected in the larvae, maximum localization
369 was found in the gut and liver regions. Treatment with stabilized Se-NP significantly ($p <$
370 0.05) reduced cellular ROS levels in CuSO₄-induced zebrafish larvae, compared to the
371 untreated stress group (**Fig. 5a-d**). The 25 µg/ml stabilized Se-NP treated with D-glucose for
372 30 minutes and 1 hour showed lower ROS levels at concentrations of 10.1 and 12.2 MFI (**Fig.**
373 **5a1,b1**). In contrast, stabilized Se-NPs reduced with orange for 30 minutes and 1 hour showed
374 lower ROS levels at concentrations of 15 µg/ml with 17.67 and 18.27 MFI (**Fig. 5c1,d1**).
375 Therefore, stabilized Se-NPs treated with D-glucose for 30 minutes could be a potential
376 antioxidant therapeutic for ROS-mediated neurodegeneration. Raju *et al.* conducted a similar
377 protocol to assess the ROS levels in zebrafish larvae exposed to H₂O₂ stress, showing higher
378 intensity in the stress group, compared to the treatment groups⁶⁸.





379 **Fig. 5 Live Cell Imaging *In Vivo* in the Zebrafish Larvae Model at 96 HPF:** DCFDA staining (a&a1)
 380 stabilized Se-NPs reduced with D-glucose for 30 minutes &MFI; (b&b1) stabilized Se-NPs reduced with D-
 381 glucose for 1 hour &MFI; (c&c1) stabilized Se-NPs reduced with orange peel extract for 30 minutes &MFI;
 382 (d&d1) stabilized Se-NPs reduced with orange peel extract for 1 hour &MFI. DPPP staining (e&e1) stabilized
 383 Se-NPs reduced with D-glucose for 30 minutes &MFI; (f&f1) stabilized Se-NPs reduced with D-glucose for 1
 384 hour &MFI. (g&g1) stabilized Se-NPs reduced with orange peel extract for 30 minutes &MFI; (h&h1)
 385 stabilized Se-NPs reduced with orange peel extract for 1 hour &MFI. The data were considered significant ($p <$
 386 0.05) and marked by the symbol “***”.

387 Determination of Live Cell Lipid Peroxidation

388 To determine the LPO levels in zebrafish larvae (96 hpf), DPPP fluorescent staining
 389 was conducted. The control group exhibited lower LPO levels at 10.67 MFI. Zebrafish larvae
 390 exposed to CuSO_4 showed increased LPO levels of 24.68 MFI. Treatment with stabilized Se-
 391 NPs significantly ($p < 0.05$) reduced LPO levels in CuSO_4 -induced stress groups compared to
 392 the untreated stress group (**Fig. 5e-h**). However, treatment with stabilized Se-NPs reduced
 393 with D-glucose for 30 minutes and 1 hour showed significantly lower intensity at the
 394 concentration of 25 $\mu\text{g}/\text{ml}$ with 11.35 and 13.17 MFI (**Fig. 5e1,f1**). In contrast, stabilized Se-
 395 NPs reduced with orange for 30 minutes and 1 hour showed lower intensity at the
 396 concentration of 15 $\mu\text{g}/\text{ml}$ with 15.78 and 16.37 MFI (**Fig. 5g1,h1**). Raju *et al.* performed a
 397 similar protocol to assess the LPO levels in zebrafish larvae exposed to H_2O_2 stress, showing
 398 similar upregulation in intensity in the stress group, compared to the treatment groups⁶⁸.

399 Estimation of AChE activity

400 Compared to the control group, zebrafish larvae exposed to CuSO_4 showed a
 401 significant decrease in AChE levels dropping from 1.14 $\mu\text{mol}/\text{ml}$ to 0.76 $\mu\text{mol}/\text{ml}$. Treatment
 402 with 25 $\mu\text{g}/\text{ml}$ stabilized Se-NPs reduced with D-glucose for 30 minutes and 1 hour, in
 403 CuSO_4 -exposed zebrafish larvae resulted in a dose-dependent increase in AChE levels,
 404 reaching 1.04 and 0.97 $\mu\text{mol}/\text{ml}$ (**Fig. 6a,b**), respectively. Conversely, treatment with
 405 stabilized Se-NPs reduced with orange peel extract for 30 minutes and 1 hour, only restored




406 the AChE concentration up to 0.95 and 0.90 $\mu\text{mol/ml}$ respectively (**Fig. 6c,d**). This suggests
407 that stabilized Se-NPs reduced with D-glucose for 30 minutes significantly restored AChE
408 concentration. A study focusing on pentylentetrazole-induced oxidative stress demonstrated
409 that pentylentetrazole-exposed mice treated with Se-NPs showed improved AChE levels
410 compared to untreated mice⁶⁹. Therefore, stabilized Se-NPs regulated CuSO_4 -induced neuron
411 damage and protected the central nervous system (CNS).

412 **Estimation of Locomotor Activity**

413 To measure the locomotor activity of zebrafish larvae and determine cognitive
414 alterations in the CNS, neurobehavior will be assessed based on the distance travelled by the
415 zebrafish larvae (in meters). Treatment with 25 $\mu\text{g/ml}$ of stabilized Se-NPs, reduced with
416 glucose for 30 minutes and 1 hour, improved cognitive behaviour by restoring the covered
417 distance to 93.40 m and 78.79 m in the CuSO_4 exposed zebrafish larvae group (**Fig. 6e-n**).
418 Conversely, treatment with stabilized Se-NPs reduced with orange for 30 minutes and 1 hour
419 at a concentration of 15 $\mu\text{g/ml}$ only improved cognitive behaviour by 46.48 m and 44.16
420 m (**Fig. 6o-x**). The control group exhibited normal cognitive behaviour with an estimated
421 travelled distance of 102.60 m (**Fig. 6y**). Following CuSO_4 exposure, the zebrafish larvae
422 could only travel 16.2 m due to stress effects (**Fig. 6z**), which was restored by approximately
423 91% with D-glucose reduced nano-Se. It is already established that zinc oxide nanoparticles
424 increase oxidative stress and impair cognitive function by decreasing the expression of Cyclic
425 Adenosine Monophosphate response element binding protein (CREB), phosphorylated CREB,
426 and synapsin I age-dependently⁷⁰. At the neuromuscular junction, acetylcholine is primarily
427 released by the motor neuron, acting as a neurotransmitter and regulating fast synaptic
428 currents essential for precise locomotion control⁷¹. Li *et al.* reported that alterations in the
429 central nervous system can be determined by the behavioral changes in animals⁷², indicating
430 that stabilized Se-NPs did not affect the central nervous system. D-glucose reduced nano-Se
431 restores the AChE concentration which is directly associated with the formation and release
432 of acetylcholine through synaptic vesicles and controls cognitive properties without altering
433 behavior.





434 **Fig.6 AChE assay and Locomotory Analysis *in vivo* in zebrafish Larvae Treated with Stabilized Se-NPs.**
 435 AChE assay of (a-b) reduced with D-glucose for 30 minutes and 1 hour, (c-d) reduced with orange peel extract
 436 for 30 minutes and 1 hour. Locomotor analysis of stabilized Se-NPs reduced with D-glucose for 30 minutes (e) 5
 437 µg/ml, (f) 10 µg/ml, (g) 15 µg/ml, (h) 20 µg/ml, (i) 25 µg/ml; stabilized Se-NPs reduced with D-glucose for 1
 438 hour (j) 5 µg/ml, (k) 10 µg/ml, (l) 15 µg/ml, (m) 20 µg/ml, (n) 25 µg/ml; stabilized Se-NPs reduced with orange
 439 peel extract for 30 minutes (o) 5 µg/ml, (p) 10 µg/ml, (q) 15 µg/ml, (r) 20 µg/ml, (s) 25 µg/ml; stabilized Se-
 440 NPs reduced with orange peel extract for 1 hour (t) 5 µg/ml, (u) 10 µg/ml, (v) 15 µg/ml, (w) 20 µg/ml, (x) 25
 441 µg/ml; Control (y) Untreated; CuSO₄; (z) 20 µM. The data were considered significant (p < 0.05) and marked by
 442 the symbol “*”.

443 CONCLUSION

444 In the ETC, mitochondria are a significant source of ROS. Increased ROS production
 445 can occur due to impaired mitochondrial function disrupting cellular homeostasis by reducing
 446 antioxidant defences and increasing lipid peroxidation. This can lead to various illnesses,
 447 including neurodegeneration. Enzymes like SOD, CAT, and GSH act as defense mechanisms
 448 to neutralize ROS. One of the essential proteins involved in the production of glutathione is
 449 selenoproteins. Deficiency of these selenoproteins also plays a role in decreasing antioxidant
 450 enzymes. However, there are several commercial drugs available, such as Coenzyme Q10, N-
 451 acetylcysteine, edaravone, Non-Steroidal Anti-Inflammatory Drugs, corticosteroids,
 452 memantine, riluzole, selegiline, levodopa, carbidopa, donepezil, etc., that can regulate
 453 oxidative stress and enhance neuroprotection. Many researchers have used nanoparticles as
 454 carriers to deliver drugs to the target site. These nanoparticles can be considered
 455 therapeutic due to their high precision, less toxic profile, and ability to cross the blood-brain



456 barrier. Se-NPs have attracted significant interest as a carrier for various applications,
457 especially in medicine. Generally, they are biocompatible and do not exhibit toxicity
458 compared to other forms of Se. The strong antioxidant properties of Se-NPs make them
459 effective ROS scavengers that protect cells from oxidative damage.

460 In our study, mussel-extracted Se was used as a rich source of Se for the synthesis of
461 Se-NPs. Saline extraction yielded a higher amount compared to the buffer extraction method.
462 FTIR peaks indicated the presence of metal, stabilizer, and reducing agents used. The size of
463 the nanoparticles depended on the reducing agent. D-Glucose efficiently produced nearly
464 spherical nano-Se of 20 nm size with potential therapeutic approaches. A comparison between
465 reducing agents showed that a 30-minute reduction with D-glucose produced potent nano-
466 Se in reducing oxidative stress and improving survival rates in CuSO₄ stress-induced
467 zebrafish larvae. In the stress group, *in-vivo* treatment with 5-25 µg/ml of stabilized Se-NPs
468 reduced with D-glucose showed no toxic effects and survival rates improved in a
469 concentration-dependent manner. On the other hand, orange-reduced stabilized Se-NPs were
470 found to be non-toxic only up to 15 µg/ml. Moreover, YSE was found to be developed above
471 those concentrations under stress-induced zebrafish larvae *in vivo*. All stabilized Se-NPs
472 showed concentration-dependent DPPH scavenging activity and concentration-independent
473 ABTS scavenging activity. However, the highest scavenging capacity was recorded with nano-
474 Se reduced with D-glucose for 30 minutes. *In-vivo* enzymatic analysis of stabilized Se-NPs
475 reduced with D-glucose for 30 minutes showed a remarkable improvement in antioxidant
476 enzyme levels while decreasing LPO and NO levels in zebrafish larvae. They restored the
477 enzyme levels by producing SOD, CAT, GSH, GST, which may be NRF2 dependent
478 mechanism and significantly reduced the MDA and NO levels in a concentration-dependent
479 manner. The qPCR confirmed that nearly a 2-fold enhancement of antioxidant genes was
480 mitigating cellular ROS. Live cell imaging also supported the therapeutic property of D-
481 glucose-reduced nano-Se. Additionally, D-glucose reduced nano-Se enhanced AChE levels in
482 a dose-dependent manner. Locomotor analysis confirmed that D-glucose reduced, and
483 stabilized Se-NPs did not disrupt CNS function and improved cognitive functions in stress-
484 induced zebrafish larvae. Thus, treatment with 25 µg/ml of D-Glucose reduced nano-Se
485 upregulated the antioxidant gene expression, downregulated LPO and NO levels with an
486 enhancement of AChE production which directly influences the release of acetylcholine from
487 synaptic vesicles and regulates cognitive function without altering the behavior of the larvae.
488 Therefore, D-glucose-reduced Se-NPs could be a potential therapeutic option to reduce
489 oxidative stress and improve cognitive function in oxidative stress-related diseases and
490 disorders. This characteristic makes them safer for therapeutic applications.

491 Future advancements in combined therapy could involve the integration of Se-NPs
492 with other therapeutic agents to enhance their efficacy. Combining Se-NPs with traditional
493 antioxidants, anti-inflammatory drugs, or targeted delivery systems may synergize their
494 effects and provide a more effective approach to regulate oxidative stress and stress-related
495 diseases. Further research is necessary on Se-NPs to make significant advancements in the
496 management and treatment of various debilitating conditions, as they have the ability to
497 enhance endogenous antioxidant enzymes and cross the blood-brain barrier.

498 MATERIALS AND METHODS

499 Chemicals Used

500 Sodium Chloride (NaCl) was purchased from Merck (CAS No: 7647-14-5), Tris
501 (hydroxymethyl) aminomethane was purchased from Thermofisher Scientific (CAS No: 77-



502 86-1). L-Ascorbic acid (CAS No: 50-81-7), Hydrogen peroxide (H₂O₂; CAS: 7722-84-1) and
503 Hydrochloric acid (CAS No: 7647-01-0) were purchased from Sigma-Aldrich. Magnesium
504 chloride (CAS No: 7786-30-3), Calcium chloride (CAS No: 10043-52-4), Sodium phosphate
505 dibasic (CAS No: 7558-79-4), Potassium phosphate monobasic (CAS No: 7778-77-0),
506 Potassium chloride (CAS No: 7447-40-7), NitroBlue Tetrazolium salt (NBT; CAS No: 298-
507 83-9), L-Methionine (CAS No: 63-68-3), Riboflavin (CAS No: 83-88-5), Thiobarbituric acid
508 (TBA; CAS No: 504-17-6), Trichloroacetic acid (TCA; Cc: 76-03-9), Griess reagent (EC:
509 215-981-2), 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB; CAS No: 69-78-3), Potassium
510 phosphate dibasic (CAS No: 7758-11-4), 1-chloro 2,4- dinitrobenzene (CAS No: 97-00-7)
511 was purchased from Sigma-Aldrich. BSA was purchased from Sisco Research Laboratories
512 (SRL; CAS No: 9048-46-8). 2,2-Diphenyl-1-Picrylhydrazyl (DPPH; CAS No: 1898-66-4)
513 and 2,2'-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid (ABTS salt; CAS No: 30931-67-
514 0), Dichlorofluorescein diacetate (DCFHDA; CAS No: 2044-85-1), 2,2-Diphenyl-1-
515 Picrylhydrazyl (DPPH; CAS No: 1898-66-4), Potassium Persulfate (CAS No: 7727-21-1),
516 Ethylenediaminetetraacetic acid (EDTA; CAS No: 60-00-4) were purchased from Sisco
517 Research Laboratories (SRL). RDP Trio™ Reagent was collected from HiMedia (SKU:
518 MB566) and AURA 2x One-Step RT-PCR Master Mix was collected from AURA
519 Biotechnologies Pvt Ltd (ABT-18S). Glassware was purchased from Borosil® and 96-well
520 ELISA plates were purchased from ThermoFisher Scientific®.

521 **Extraction of Selenium from Mussels**

522 **a) Collection and Preparation of Mussel**

523 Mussels (Domain: Eukaryota; Kingdom: Animalia; Phylum: Mollusca; Class:
524 Bivalvia; Order: Mytilida; Family: Mytilidae; Genus: *Perna*; Species: *viridis*) were freshly
525 collected whole from Kasimedu Fishing Harbour, Tondiarpet (N 13° 7' 22.4292", E 80° 17'
526 36.4272"), Chennai. The mussels were thoroughly cleaned to remove sand and debris. The
527 shells were then opened, and the tissue was carefully scraped and rinsed with distilled water.
528 After removing excess water, the collected tissue was dried overnight. The dried mussel
529 tissue was subsequently stored at 4°C for use in further experiments.

530 **b) Extraction of Se**

531 *i. Extraction with 0.8% Saline:*

532 A 0.8% saline solution was freshly prepared by dissolving 8 g of sodium chloride
533 (NaCl) in 1000 ml of distilled water. Next, 8.5 g of mussel tissue was weighed and ground
534 with 100 ml of the 0.8% saline solution using a mortar and pestle. The resulting mixture was
535 centrifuged at 5000 rpm for 30 minutes at room temperature (37°C). This centrifugation step
536 was repeated until no pellet was observed. The collected pellet was dried at 60°C in a hot air
537 oven. Once completely dry, the pellet was ground into a fine powder using a mortar and
538 pestle⁷³.

539 *ii. Extraction with 50mM Tris-HCl Buffer pH7.4:*

540 A Tris-HCl buffer (pH 7.4) was freshly prepared by dissolving 2.65 g of Tris base and
541 4.44 g of HCl in 1000 ml of distilled water. Next, 8.5 g of mussel tissue was weighed and
542 ground with 100 ml of the Tris-HCl buffer using a mortar and pestle. Following the method
543 previously described for selenium purification fine Se powder was obtained⁷³.

544 **Synthesis of Se-NPs**

545 A green synthesis approach was used to produce Se-NPs by reducing mussel-derived
546 Se, with D-glucose and crude orange peel extract (Schematically represented in flowchart).



547 Fresh oranges were purchased from local markets, washed, and their peels were collected. The
548 collected orange peels were blended with 100g in 500ml of water using a mixer, filtered, and
549 stored at 4°C as needed. 0.2 g of mussel-derived selenium was dissolved in 50 ml of distilled
550 water using a sonicator. In a round bottom flask, 50 ml of the dissolved mussel-derived Se
551 was combined with 15 ml of 0.25 M D-glucose and 15 ml of crude orange peel extract
552 separately. Both reduction processes were carried out at two different intervals, 30 minutes
553 and 1 hour, with and without a stabilizer (5% BSA), using a heating mantle. The resulting
554 mixture was centrifuged at 5000 rpm for 30 minutes at 37°C (room temperature). The
555 collected pellets were then dried at 60°C in a hot air oven. Once completely dried, the pellets
556 were ground into a fine powder using a mortar and pestle^{47,74}. These synthesized Se-NPs
557 were used for further experimental investigations.

558 **Characterization of Mussel extracted Se and Se-NPs**

559 The Se-NPs underwent a comprehensive analysis utilizing various analytical
560 techniques. Inductively Coupled Plasma Optical Emission Spectroscopy (ICP-OES) was
561 conducted using a PERKIN ELMER OPTIMA 5300 DV ICP-OES to determine trace
562 element concentrations⁷⁵. X-ray diffraction (XRD) and crystallography studies were carried
563 out using a BRUKER D8 ADVANCE POWDER XRD. The measurements were taken over a
564 2θ range spanning from 10 to 80 degrees⁷⁶. Fourier-transform infrared (FTIR) spectroscopy
565 was used to examine the presence of functional groups. This analysis was performed using a
566 Nicolet Summit FTIR instrument (ThermoFisher Scientific) operating in diffuse reflectance
567 mode. The detectors used were DTGS KBr, and 16 scans were recorded over a wavenumber
568 range from 400 to 4000 cm⁻¹⁷⁶. The resulting spectra were plotted with wavenumber (cm⁻¹)
569 on the X-axis and transmittance (%) on the Y-axis using OriginPro 8.5 Software. Scanning
570 Electron Microscope (SEM) analysis was conducted using a Hitachi Model: S-3400N to
571 elucidate the surface morphology of the Se-NPs. The SEM was operated at 15 kV in high
572 vacuum (HV) mode with semiconductor secondary electron (SE) detection. The acquired
573 images were further analyzed for size distribution using ImageJ software⁷⁶. TEM and SAED
574 (FEI Tecnai G2 20 S-TWIN TEM) was operated at 200 kV. Particle size analysis and Zeta
575 potential were done using nanoPartica SZ-100V2 (Horiba)⁷⁶.

576 ***In Vitro* Antioxidant Studies**


577 To evaluate the *in vitro* antioxidant potential of stabilized Se-NPs, DPPH and ABTS
578 assays were conducted following methods outlined in previous studies^{77,78}. Stock
579 solutions containing 50 μM ascorbic acid and 1 mg/ml of Se-NPs were prepared from which
580 working solutions of 5, 10, 15, 20 and 25 μg/ml were derived. These concentrations
581 were fixed based on previously reported studies⁷⁹ and were consistently utilized throughout the
582 study. Three individual experiments were performed.

583 *a) DPPH Assay*

584 In this method, a DPPH solution of 300 μM was mixed with 50 μM ascorbic acid and
585 various concentrations of stabilized Se-NPs (5, 10, 15, 20, and 25 μg/ml) in a 96-well ELISA
586 plate. The plates were then incubated in darkness for 30 minutes. After the incubation period,
587 the absorbance of the samples was measured at 517 nm using a ThermoFisher Scientific®
588 microplate reader.

589 *b) ABTS Assay*

590 The reaction mixture of 7 mM ABTS salt prepared with 2.45 mM potassium
591 persulfate (1:1) was incubated for 24 hours in the dark at room temperature. To achieve an



592 absorbance of 0.7 ± 2 at 734 nm, 20X PBS was used to dilute the ABTS solution, 50 μM
593 ascorbic acid was used as a positive control along with stabilized Se-NPs (5, 10, 15, 20 and
594 25 $\mu\text{g/ml}$). These were added to a 96-well ELISA plate along with the ABTS solution. The
595 plate was then incubated at room temperature in the dark for an hour. The samples were
596 measured at 734 nm using a ThermoFisher Scientific® microplate reader.

597 ***In Vivo* Developmental Toxicity Studies**

598 *a) Zebrafish Maintenance and Embryo Collection*

599
600 Adult male and female zebrafish were obtained from Tarun Fish Farm in
601 Manimangalam (latitude N 12° 55' 1" and longitude E 80° 2' 29"), Chennai. Based on
602 Institutional Ethical Committee Guidelines (SU/CLAR/RD/001/2023), adult zebrafish were
603 maintained in a 19 L glass tank at 28.5°C with a 14/10 hour light/dark cycle. The fish were
604 fed live *Artemia salina* (brine shrimp) threetimes a day. Breeding was initiated after 20 days
605 of acclimatization in lab conditions. Two separate breeding groups were placed in a spawning
606 tank with a ratio of 1:1 (male:female). To prevent the female fish from swallowing the eggs, a
607 mesh was placed at the bottom of the spawning tank. Embryos were collected from the
608 breeding unit 30 minutes after the onset of light. The embryos were rinsed with freshly
609 prepared E3 medium⁸⁰ and kept at $26 \pm 1^\circ\text{C}$ (OECD, 2013) until the experiments were
610 conducted.

611 *b) In Vivo Developmental Toxicity Test*

612
613 Zebrafish embryos (4 hours post fertilization; hpf) were transferred to a 12-well plate
614 ($n=10$ embryos per well). The control group embryos were left untreated. The embryos were
615 exposed to CuSO_4 (20 μM ; stress group) and CuSO_4 exposed group treated with 5 different
616 concentrations of stabilized Se-NPs(5-25 $\mu\text{g/ml}$) every 24 hours until 96 hours. These
617 concentrations were fixed based on previously reported studies^{51,81,82}and were consistently
618 utilized throughout the study. The experiment was conducted in triplicate. The development
619 of the zebrafish embryos was observed under a microscope at 4X magnification^{83,84}.

620 ***In Vivo* Antioxidant Studies**

621 For enzymatic assays, the CuSO_4 -exposed larvaetreated with stabilized Se-NPs(5-25
622 $\mu\text{g/ml}$) were homogenized ($n = 20$, all experiments were conducted in triplicate) in a solution
623 containing 100 mM Tris HCl buffer (pH 7.8 at 4°C) with 150 mM potassium chloride and 1
624 mM EDTA, at 96 hpf. The homogenized sample was centrifuged at 10000 rpm for 15
625 minutes and the supernatant was used for further enzymatic analysis⁸⁵. The Bradfordmethod
626 was used for protein estimation⁸⁶.

627 *a) Superoxide Dismutase (SOD) Assay*

628
629 A reaction mixture consisting of 50mM phosphate buffer (pH 7.8), 100 μM EDTA,
630 750 μM NBT, 130 mM methionine, and 20 μM riboflavin was prepared and added to the 50
631 μl larval homogenate. The mixture was incubated under light for 20 minutes and absorbance
632 was measured at 560 nm⁸⁴.

633 *b) Catalase (CAT) Assay*

634 The catalase assay was done based on a previously reported study⁸⁷. To determine
635 catalase activity, 100 μl of buffered H_2O_2 was added to 50 μl of the sample. The absorbance
636 was noted at 240nm for 2 minutes with an interval of 15 seconds using spectrophotometry.



637 *c) Lipid Peroxidation (LPO) Assay*

638 MDA levels were determined using the thiobarbituric acid method⁸⁷. To a 100 μ l
639 sample, 0.1 ml of 5% trichloroacetic acid was added and incubated for 15 minutes on ice.
640 Then, 0.2 ml of 0.67% thiobarbituric acid was added and incubated for 30 minutes at 100°C
641 in a water bath. The sample was cooled immediately on ice for 20 minutes and then
642 centrifuged at 2000 rpm for 10 minutes at 4°C. The absorbance was recorded at 535nm⁸⁸.

643 *d) Nitric Oxide (NO) Assay*

644 The Griess method was employed to determine NO levels, with slight modifications⁸⁹.
645 100 μ l Griess reagent was added to the 100 μ l homogenized larvae sample. The samples were
646 incubated for 25 minutes at room temperature. The absorbance was noted at 540 nm.

647 *e) Reduced Glutathione (GSH) and Glutathione S-Transferase(GST) Assay*

648 GSH and GST assays were performed as described by Issac *et al.*⁸⁴, with minor
649 modifications. To estimate GSH levels, a 100 μ l larvae sample was mixed with 50 μ l of 20
650 mM DTNB and 150 μ l of 100 mM potassium phosphate buffer with a pH of 7.4. The
651 absorbance was measured at 412 nm. To determine GST levels, a 100 μ l reaction mixture
652 containing 10 μ M GSH and 60 μ M 1-chloro 2,4-dinitrobenzene was prepared and added to 50
653 μ l of the larvae sample, and the absorbance was recorded at 340 nm.

654 **Antioxidant Gene Expression by Real-Time Polymerase Chain Reaction (RT-PCR)**

655 RNA was extracted from the experimental homogenized zebrafish larvae using RDP
656 Trio™ Reagent. The primers for antioxidant enzymes and housekeeping genes were designed
657 using NCBI's Primer-BLAST (**Table 1**). Expression of the genes was analyzed using AURA
658 2x One-Step RT-PCR Master Mix. The reverse transcription process starts with a single cycle
659 at a temperature ranging between 44-50°C lasting for 15 minutes, followed by enzyme
660 activation, at 95°C for 3 minutes. The denaturation step (repeated for 40 cycles) was at 95°C
661 for 10 seconds. Annealing was done at 60°C for 45 seconds, and the extension process was
662 performed at 72°C for 15 seconds. The fold change was calculated using the $2^{-\Delta\Delta ct}$ method⁷⁷.

663 **Estimation of Acetylcholinesterase (AChE)**

664 The larvae were analyzed for cognitive impairments after exposure to CuSO₄ and
665 treatment with stabilized Se-NPs. The homogenized larvae were centrifuged at 5000 rpm for
666 15 minutes. The supernatant was mixed with the reaction mixture containing 3.3 mM DTNB
667 and incubated for 20 minutes. The absorbance was recorded at 412 nm in 1 minute intervals
668 following the acetylcholine iodide addition^{72,77}.

669 **Cognitive Behavior Analysis**

670 The locomotor abnormalities of the zebrafish larvae were evaluated by analyzing the
671 swimming behavior pattern⁹⁰. At the end of the exposure period (7 dpf) each exposure group
672 (n = 3 larvae/well; experiments were conducted in triplicate) was placed in a white chambered
673 ice tray (2.5 × 3.5 cm) containing 2 ml of E3 medium prepared without methylene blue, for
674 10 minutes of acclimatization. The locomotion of larvae was recorded at the beginning of the
675 light cycle under noise-free conditions by a commercial smartphone camera after
676 acclimatization. The video was recorded for 60 seconds at 60 frames per second and
677 locomotion was plotted using UMA Tracker software⁹¹.

678 **Estimation of ROS Levels in Zebrafish Larvae**

679 All groups including the control, stress group and stabilised Se-NPs treated group
680 larvae were anaesthetized (n = 6 per group) using tricaine. The larvae were stained with
681 DCFDA (20 µg/ml) dye and incubated for 1 hour in the dark at room temperature. After
682 incubation, the stained larvae were observed pictographically under a fluorescent microscope
683 (CKX53 Microscope, Japan) and analyzed using ImageJ software⁹².

684 **Estimation of LPO Levels in Zebrafish Larvae**

685 All groups including the control, stress group and stabilised Se-NPs treated group
686 larvae were anaesthetized (n = 6 per group) using tricaine. The larvae were stained with
687 DPPP (25 µg/ml) dye and incubated for 30 minutes at room temperature. After incubation,
688 the stained larvae were observed pictographically under a fluorescent microscope (CKX53
689 Microscope, Japan) and analyzed using ImageJ software⁹².

690 **Statistical Analysis**

691 All experiments in this study were conducted in triplicate and are presented as mean ±
692 standard deviation (SD). The data was analyzed using one-way analysis of variance
693 (ANOVA) and Dunnett's Multiple Comparison Test in GraphPad Prism 5.0 (GraphPad
694 Software, Inc., San Diego, CA)⁹³. Significant results were denoted by the symbol "*" and
695 were considered significant with p < 0.05.

696 **DECLARATIONS**

697 **ETHICS APPROVAL AND CONSENT TO PARTICIPATE**

698 All experiments were conducted in accordance with the ethical guidelines for the care and
699 utilization of animals, as approved by the Institutional Ethical Committee under protocol
700 number SU/CLAR/RD/001/2023.

701 **LIVE SUBJECT STATEMENT**

702 All experiments were performed in compliance with OECD guidelines. All animal
703 procedures were performed in accordance with the Guidelines for Care and Use of
704 Laboratory Animals of Saveetha Institute of Medical and Technical Sciences, Saveetha
705 University and approved by the Institutional Animal Ethics Committee of Saveetha Medical
706 College. No human subjects were used throughout the study.

707 **CONSENT FOR PUBLICATION**

708 Not applicable

709 **AVAILABILITY OF DATA AND MATERIALS**

710 All data generated or analyzed during this study are included in this published article. Data
711 for this article, including qPCR primers are available at NCBI (NCBI: NM_131294.1; NCBI:
712 XM_021470442.1; NCBI: XM_005169592.4; NCBI: NM_001030070.2; NCBI:
713 NM_131031.2) at <https://www.ncbi.nlm.nih.gov/>; SOD:
714 https://www.ncbi.nlm.nih.gov/nuccore/NM_131294.1; CAT:
715 https://www.ncbi.nlm.nih.gov/nuccore/XM_021470442.1; GSR:



716 https://www.ncbi.nlm.nih.gov/nuccore/XM_005169592.4;GPx:
 717 https://www.ncbi.nlm.nih.gov/nuccore/NM_001030070.2;Beta
 718 https://www.ncbi.nlm.nih.gov/nuccore/NM_131031.2

View Article Online
 DOI: 10.1039/D4NA00644E
 actin:

719 SUPPLEMENTARY DATA

720 There is a supplementary file with figures, tables and raw data sheet along with the main
 721 manuscript.

722 COMPETING INTERESTS

723 The authors declare that they have no competing interests

724 FUNDING

725 This research did not receive any specific grant from funding agencies in the public,
 726 commercial, or not-for-profit sectors.

727 AUTHORS' CONTRIBUTIONS

728 SU is responsible for conducting experiments, result analysis, and figures and IP is
 729 responsible for conceptualization, result validation. Both the authors are writing the original
 730 draft and verified the final manuscript.

731 ACKNOWLEDGEMENT

732 We express our gratitude to the Saveetha School of Engineering, Saveetha Institute of
 733 Medical and Technical Sciences, Saveetha University, for providing the necessary
 734 infrastructure to carry out this work successfully.

735 FIGURE LEGENDS

736 **Fig. 1 Synthesis and Characterization of Se extracted from mussel and Se-NPs:** ICP-OES (a) Saline
 737 extracted Se; (b) Buffer extracted Se; XRD analysis (c) Saline extracted Se; (d) Buffer extracted Se; SEM (e-f)
 738 stabilized Se-NPs reduced for 30 minutes and 1hour with D-glucose; (g-h) stabilized Se-NPs reduced for 30
 739 minutes and 1hour with orange; TEM and SAED (i-j) stabilized Se-NPs reduced for 30 minutes with D-
 740 Glucose; (k-l) stabilized Se-NPs reduced for 30 minutes with orange. Yield (m) Percentage of Se yield. FTIR (n)
 741 stabilized Se-NPs reduced for 30 minutes and 1 hour with D-glucose; (o) stabilized Se-NPs reduced for 30
 742 minutes and 1 hour with orange peel extract.

743 **Fig.2 *In Vivo* Developmental Toxicity Analysis in zebrafish embryos and larvae representing, Control**
 744 **group; Stress group (CuSO₄-induced stress); and Stabilized Se-NPs (5-25 µg/ml) treatment group.** (a-b)
 745 stabilized Se-NPs reduced with D-glucose for 30 minutes and 1 hour, (c-d) stabilized Se-NPs reduced with
 746 orange peel extract for 30 minutes and 1hour. Survival rate (a1-b1) stabilized Se-NPs reduced with D-glucose
 747 for 30 minutes and 1 hour, (c1-d1) stabilized Se-NPs reduced with orange peel extract for 30 minutes and
 748 1hour. The data were considered significant ($p < 0.05$) and marked by the symbol “*”.

749 **Fig. 3 *In Vitro* Antioxidant Activity:** DPPH assay of (a-b) stabilized Se-NPs reduced with D-glucose for 30
 750 minutes and 1 hour, (c-d) stabilized Se-NPs reduced with orange peel extract for 30 minutes and 1hour. ABTS
 751 assay of (e-f) stabilized Se-NPs reduced with D-glucose for 30 minutes and 1 hour, (g-h) stabilized Se-NPs
 752 reduced with orange peel extract for 30 minutes and 1hour. The data were considered significant ($p < 0.05$) and
 753 marked by the symbol “*”.



754 **Fig. 4 *In Vivo* Antioxidant Activity of stabilized Se-NPs:** SOD assay (a-b) reduced with D-glucose for 30
 755 minutes and 1 hour, CAT assay (c-d) reduced with D-glucose for 30 minutes and 1 hour. LPO assay (e-f)
 756 reduced with D-glucose for 30 minutes and 1 hour. NO assay (g-h) reduced with D-glucose for 30 minutes and 1
 757 hour. GSH assay (i-j) reduced with D-glucose for 30 minutes and 1 hour. GST assay (k-l) reduced with D-
 758 glucose for 30 minutes and 1 hour. RT-PCR (m) reduced with D-glucose for 30 minutes (25 µg/ml). The data
 759 were considered significant ($p < 0.05$) and marked by the symbol “*”.

760 **Fig. 5 Live Cell Imaging *In Vivo* in the Zebrafish Larvae Model at 96 HPF:** DCFDA staining (a&a1)
 761 stabilized Se-NPs reduced with D-glucose for 30 minutes & MFI; (b & b1) stabilized Se-NPs reduced with D-
 762 glucose for 1 hour & MFI; (c&c1) stabilized Se-NPs reduced with orange peel extract for 30 minutes & MFI; (d
 763 & d1) stabilized Se-NPs reduced with orange peel extract for 1 hour & MFI. DPPH staining (e & e1) stabilized
 764 Se-NPs reduced with D-glucose for 30 minutes & MFI; (f & f1) stabilized Se-NPs reduced with D-glucose for 1
 765 hour & MFI. (g & g1) stabilized Se-NPs reduced with orange peel extract for 30 minutes & MFI; (h & h1)
 766 stabilized Se-NPs reduced with orange peel extract for 1 hour & MFI. The data were considered significant ($p <$
 767 0.05) and marked by the symbol “*”.

768 **Fig. 6 AChE assay and Locomotory Analysis *in vivo* in zebrafish Larvae Treated with Stabilized Se-**
 769 **NPs.** AChE assay of (a-b) reduced with D-glucose for 30 minutes and 1 hour, (c-d) reduced with orange peel
 770 extract for 30 minutes and 1 hour. Locomotor analysis of stabilized Se-NPs reduced with D-glucose for 30
 771 minutes (e) 5 µg/ml, (f) 10 µg/ml, (g) 15 µg/ml, (h) 20 µg/ml, (i) 25 µg/ml; stabilized Se-NPs reduced with D-
 772 glucose for 1 hour (j) 5 µg/ml, (k) 10 µg/ml, (l) 15 µg/ml, (m) 20 µg/ml, (n) 25 µg/ml; stabilized Se-NPs
 773 reduced with orange peel extract for 30 minutes (o) 5 µg/ml, (p) 10 µg/ml, (q) 15 µg/ml, (r) 20 µg/ml, (s) 25
 774 µg/ml; stabilized Se-NPs reduced with orange peel extract for 1 hour (t) 5 µg/ml, (u) 10 µg/ml, (v) 15 µg/ml,
 775 (w) 20 µg/ml, (x) 25 µg/ml; Control (y) Untreated; CuSO₄; (z) 20 µM. The data were considered significant ($p <$
 776 0.05) and marked by the symbol “*”.

777 TABLE LEGEND

778 **Table 1: Primer sequences used in RT-PCR**




779 **Table 1: Primer sequences used in RT-PCR**View Article Online
DOI: 10.1039/D4NA00644E

Gene	Forward Primer(5' to 3')	Reverse Primer (5' to 3')	Reference
SOD	GGTCCGCACTTCAACCCTCA	TACCCAGGTCTCCGACGTGT	NCBI: NM_131294.1
CAT	AACTGTGGAAGGAGGGTCGC	CGCTCTCGGTCAAATGGGC	NCBI: XM_021470442.1
GSR	GATGGGCACCATAGCTAACCC	CATGAGCAGGAAGCAACACCC	NCBI: XM_005169592.4
GPx	AACTACACTCAGCTTGCGGC	TCCGCTTCACTTCCAGGCTC	NCBI: NM_001030070.2
β -actin	AAGCTGTGACCCACCTCACG	GGCTTTGCACATACCGGAGC	NCBI: NM_131031.2

780



781 EXTRACTION METHOD FLOWCHART

View Article Online
DOI: 10.1039/D4NA00644E

783 REFERENCES

- 784 1 L. D. Osellame, T. S. Blacker and M. R. Duchon, *Best Pract. Res. Clin. Endocrinol.*
785 *Metab.*, 2012, **26**, 711–723.
- 786 2 L.-D. Popov, *Cell. Signal.*, 2023, **109**, 110794.
- 787 3 F. A. Bustamante-Barrientos, N. Luque-Campos, M. J. Araya, E. Lara-Barba, J. de
788 Solminihaç, C. Pradenas, L. Molina, Y. Herrera-Luna, Y. Utreras-Mendoza, R.
789 Elizondo-Vega, A. M. Vega-Letter and P. Luz-Crawford, *J. Transl. Med.*, 2023, **21**,
790 613.
- 791 4 D. M. Niyazov, S. G. Kahler and R. E. Frye, *Mol. Syndromol.*, 2016, **7**, 122–137.
- 792 5 R. N. L. Lamptey, B. Chaulagain, R. Trivedi, A. Gothwal, B. Layek and J. Singh, *Int.*
793 *J. Mol. Sci.*, 2022, **23**, 1851.
- 794 6 W. Chen, H. Zhao and Y. Li, *Signal Transduct. Target. Ther.*, 2023, **8**, 333.
- 795 7 T. Vezza, P. Díaz-Pozo, F. Canet, A. M. de Marañón, Z. Abad-Jiménez, C. García-
796 Gargallo, I. Roldan, E. Solá, C. Bañuls, S. López-Domènech, M. Rocha and V. M.
797 Víctor, *World J. Mens. Health*, 2022, **40**, 399.
- 798 8 S. K. Bardaweel, M. Gul, M. Alzweiri, A. Ishaqat, H. A. ALSalamat and R. M.
799 Bashatwah, *Eurasian J. Med.*, 2018, **50**, 193–201.
- 800 9 G. Pizzino, N. Irrera, M. Cucinotta, G. Pallio, F. Mannino, V. Arcoraci, F. Squadrito,
801 D. Altavilla and A. Bitto, *Oxid. Med. Cell. Longev.*, 2017, **2017**, 1–13.
- 802 10 Tsatsakis, Docea, Calina, Tsarouhas, Zamfira, Mitrut, Sharifi-Rad, Kovatsi, Siokas,
803 Dardiotis, Drakoulis, Lazopoulos, Tsitsimpikou, Mitsias and Neagu, *J. Clin. Med.*,
804 2019, **8**, 1295.
- 805 11 K. H. Al-Gubory, C. Garrel, P. Faure and N. Sugino, *Reprod. Biomed. Online*, 2012,
806 **25**, 551–560.
- 807 12 M. Sharifi-Rad, N. V. Anil Kumar, P. Zucca, E. M. Varoni, L. Dini, E. Panzarini, J.
808 Rajkovic, P. V. Tsouh Fokou, E. Azzini, I. Peluso, A. Prakash Mishra, M. Nigam, Y.
809 El Rayess, M. El Beyrouthy, L. Polito, M. Iriti, N. Martins, M. Martorell, A. O. Docea,
810 W. N. Setzer, D. Calina, W. C. Cho and J. Sharifi-Rad, *Front. Physiol.*, ,
811 DOI:10.3389/fphys.2020.00694.
- 812 13 S. E. Laouini, A. Bouafia, A. V. Soldatov, H. Algarni, M. L. Tedjani, G. A. M. Ali and
813 A. Barhoum, *Membranes (Basel)*, 2021, **11**, 468.
- 814 14 C. E. Probst, P. Zrazhevskiy, V. Bagalkot and X. Gao, *Adv. Drug Deliv. Rev.*, 2013,
815 **65**, 703–718.
- 816 15 Z. S. Bailey, E. Nilson, J. A. Bates, A. Oyalowo, K. S. Hockey, V. S. S. S. Sajja, C.
817 Thorpe, H. Rogers, B. Dunn, A. S. Frey, M. J. Billings, C. A. Sholar, A. Hermundstad,
818 C. Kumar, P. J. VandeVord and B. A. Rzigalinski, *J. Neurotrauma*, 2020, **37**, 1452–
819 1462.
- 820 16 F. Karimi, N. Rezaei-savadkouhi, M. Uçar, A. Aygun, R. N. Elhouda Tiri, I. Meydan,
821 E. Aghapour, H. Seckin, D. Berikten, T. Gur and F. Sen, *Food Chem. Toxicol.*, 2022,
822 **169**, 113406.



- 823 17 R. Gil-Gonzalo, D. A. Durante-Salmerón, S. Pouri, E. Doncel-Pérez, A. R. Alcántara,
824 I. Aranaz and N. Acosta, *Pharmaceutics*, , DOI:10.3390/pharmaceutics16081036. View Article Online
DOI: 10.1039/D4NA00644E
- 825 18 K. R. Trabbic, K. A. Kleski and J. J. Barchi, *ACS Bio Med Chem Au*, 2021, **1**, 31–43.
- 826 19 A. M. El Shafey, *Green Process. Synth.*, 2020, **9**, 304–339.
- 827 20 M. Kieliszek, *Molecules*, 2019, **24**, 1298.
- 828 21 L. Di Renzo, P. Gualtieri, G. Frank and A. De Lorenzo, *Nutrients*, 2023, **15**, 2253.
- 829 22 F. Barzegarparay, H. Najafzadehvarzi, R. Pourbagher, H. Parsian, S. M. Ghoreishi and
830 S. Mortazavi-Derazkola, *Biomass Convers. Biorefinery*, 2024, **14**, 25369–25378.
- 831 23 F. Chen, X. H. Zhang, X. D. Hu, P. D. Liu and H. Q. Zhang, *Artif. Cells,*
832 *Nanomedicine, Biotechnol.*, 2018, **46**, 937–948.
- 833 24 N. Bisht, P. Phalswal and P. K. Khanna, *Mater. Adv.*, 2022, **3**, 1415–1431.
- 834 25 J. T. Tendenedzai, E. M. N. Chirwa and H. G. Brink, *Sci. Rep.*, 2023, **13**, 20379.
- 835 26 G. Rusip, S. Ilyas, I. N. E. Lister, C. N. Ginting and I. Mukti, *F1000Research*, 2022,
836 **10**, 1061.
- 837 27 O. A. Mahdy, S. Z. Abdel-Maogood, M. Abdelsalam and M. A. Salem, *BMC Vet. Res.*,
838 2024, **20**, 60.
- 839 28 N. Liu, L. Tong, K. Li, Q. Dong and J. Jing, *Molecules*, 2024, **29**, 2414.
- 840 29 S. Salaramoli, H. Amiri, H. R. Joshaghani, M. Hosseini and S. I. Hashemy, *Metab.*
841 *Brain Dis.*, 2023, **38**, 2055–2064.
- 842 30 N. Zakeri, M. R. Kelishadi, O. Asbaghi, F. Naeini, M. Afsharfar, E. Mirzadeh and S.
843 kasma Naserizadeh, *PharmaNutrition*, 2021, **17**, 100263.
- 844 31 O. M. El-Borady, M. S. Othman, H. H. Atallah and A. E. Abdel Moneim, *Heliyon*,
845 2020, **6**, e04045.
- 846 32 M. Iranifam, M. Fathinia, T. Sadeghi Rad, Y. Hanifehpour, A. R. Khataee and S. W.
847 Joo, *Talanta*, 2013, **107**, 263–269.
- 848 33 H. Amani, R. Habibey, F. Shokri, S. J. Hajmiresmail, O. Akhavan, A. Mashaghi and
849 H. Pazoki-Toroudi, *Sci. Rep.*, 2019, **9**, 6044.
- 850 34 T. Yin, L. Yang, Y. Liu, X. Zhou, J. Sun and J. Liu, *Acta Biomater.*, 2015, **25**, 172–
851 183.
- 852 35 L. Qiao, Y. Chen, X. Song, X. Dou and C. Xu, *Int. J. Nanomedicine*, 2022, **Volume**
853 **17**, 4807–4827.
- 854 36 Z. Li, H. Liang, Y. Wang, G. Zheng and L. Yang, *ACS Appl. Nano Mater.*, 2024, **7**,
855 20411–20424.
- 856 37 M. Zhu, Y. Zhang, C. Zhang, L. Chen and Y. Kuang, *J. Biomater. Appl.*, 2023, **38**,
857 109–121.
- 858 38 H. Zhao, J. Song, T. Wang and X. Fan, *Nanomedicine Nanotechnology, Biol. Med.*,
859 2024, **59**, 102755.



- 860 39 B. Bálint, K. Balogh, M. Mézes and B. Szabó, *Eur. J. Soil Biol.*, 2021, **107**, 103361. View Article Online
DOI: 10.1039/D4NA00644E
- 861 40 S. Shoeibi, P. Mozdziak and A. Golkar-Narenji, *Top. Curr. Chem.*, 2017, **375**, 88.
- 862 41 T. M. Sakr, M. Korany and K. V. Katti, *J. Drug Deliv. Sci. Technol.*, 2018, **46**, 223–
863 233.
- 864 42 S. Hariharan and S. Dharmaraj, *Inflammopharmacology*, 2020, **28**, 667–695.
- 865 43 A. Tyburska, K. Jankowski, A. Ramsza, E. Reszke, M. Strzelec and A. Andrzejczuk, *J.*
866 *Anal. At. Spectrom.*, 2010, **25**, 210–214.
- 867 44 R. Hassanien, A. A. I. Abed-Elmageed and D. Z. Husein, *ChemistrySelect*, 2019, **4**,
868 9018–9026.
- 869 45 A. M. El Badawy, K. G. Scheckel, M. Suidan and T. Tolaymat, *Sci. Total Environ.*,
870 2012, **429**, 325–331.
- 871 46 T. Nie, H. Wu, K.-H. Wong and T. Chen, *J. Mater. Chem. B*, 2016, **4**, 2351–2358.
- 872 47 S. S. Salem, M. S. E. M. Badawy, A. A. Al-Askar, A. A. Arishi, F. M. Elkady and A.
873 H. Hashem, *Life*, 2022, **12**, 893.
- 874 48 C. Van der Horst, B. Silwana, E. Iwuoha and V. Somerset, *Anal. Lett.*, 2015, **48**, 1311–
875 1332.
- 876 49 A. Bhattacharyya, R. Prasad, A. A. Buhroo, P. Duraisamy, I. Yousuf, M. Umadevi, M.
877 R. Bindhu, M. Govindarajan and A. L. Khanday, *J. Nanosci.*, 2016, **2016**, 1–7.
- 878 50 V. Alagesan and S. Venugopal, *Bionanoscience*, 2019, **9**, 105–116.
- 879 51 K. Kalishwaralal, S. Jeyabharathi, K. Sundar and A. Muthukumar, *Artif. Cells,*
880 *Nanomedicine, Biotechnol.*, 2016, **44**, 471–477.
- 881 52 S.-H. Cha, J.-H. Lee, E.-A. Kim, C. H. Shin, H.-S. Jun and Y.-J. Jeon, *RSC Adv.*, 2017,
882 **7**, 46164–46170.
- 883 53 J. Vyas and S. Rana, *Int. J. Curr. Pharm. Res.*, 2017, **9**, 147.
- 884 54 X. Zhai, C. Zhang, G. Zhao, S. Stoll, F. Ren and X. Leng, *J. Nanobiotechnology*, 2017,
885 **15**, 4.
- 886 55 S. Naz, R. Hussain, Z. Guangbin, A. M. M. Chatha, Z. U. Rehman, S. Jahan, M.
887 Liaquat and A. Khan, *Front. Vet. Sci.*, , DOI:10.3389/fvets.2023.1142042.
- 888 56 M. A. Khan, D. Singh, A. Arif, K. K. Sodhi, D. K. Singh, S. N. Islam, A. Ahmad, K.
889 Akhtar and H. R. Siddique, *Life Sci.*, 2022, **305**, 120792.
- 890 57 M. de los Á. Sariñana-Navarrete, Á. Morelos-Moreno, E. Sánchez, G. Cadenas-Pliego,
891 A. Benavides-Mendoza and P. Preciado-Rangel, *Agronomy*, 2023, **13**, 652.
- 892 58 M. Lesnichaya, E. Karpova and B. Sukhov, *Colloids Surfaces B Biointerfaces*, 2021,
893 **197**, 111381.
- 894 59 S. S. Anuse, V. SUMATHI, C. UMA, D. SANGEETHA, P. SIVAGURUNATHAN
895 and D. J. M. KUMAR, *UTTAR PRADESH J. Zool.*, 2022, 115–120.
- 896 60 O. M. El-Borady, M. S. Othman, H. H. Atallah and A. E. Abdel Moneim, *Heliyon*,
897 2020, **6**, e04045.



- 898 61 P. Horky, B. Ruttkay-Nedecky, M. Kremplova, O. Krystofova, R. Kensova, D. Hynek, View Article Online
899 P. Babula, O. Zitka, L. Zeman, V. Adam and R. Kizek, *Int. J. Electrochem. Sci.*, 2013, DOI: 10.1039/D4NA00644E
900 **8**, 6162–6179.
- 901 62 J. Mu, L. Lei, Y. Zheng, J. Liu, J. Li, D. Li, G. Wang and Y. Liu, *Antioxidants*, 2023,
902 **12**, 796.
- 903 63 G. Barchielli, A. Capperucci and D. Tanini, *Antioxidants*, 2022, **11**, 251.
- 904 64 X. Wang, C. X. Hai, X. Liang, S. X. Yu, W. Zhang and Y. L. Li, *J. Ethnopharmacol.*,
905 2010, **127**, 424–432.
- 906 65 J. Fang, H. Yin, Z. Yang, M. Tan, F. Wang, K. Chen, Z. Zuo, G. Shu, H. Cui, P.
907 Ouyang, H. Guo, Z. Chen, C. Huang, Y. Geng and W. Liu, *Ecotoxicol. Environ. Saf.*,
908 2021, **208**, 111610.
- 909 66 M. Hammad, M. Raftari, R. Cesário, R. Salma, P. Godoy, S. N. Emami and S.
910 Haghdoost, *Antioxidants*, 2023, **12**, 1371.
- 911 67 N. Handa, S. K. Kohli, A. Sharma, A. K. Thukral, R. Bhardwaj, E. F. Abd_Allah, A.
912 A. Alqarawi and P. Ahmad, *Environ. Exp. Bot.*, 2019, **161**, 180–192.
- 913 68 S. V. Raju, A. Mukherjee, P. Sarkar, P. K. Issac, C. Lite, B. A. Paray, M. K. Al-
914 Sadoon, A. R. Al-Mfarjij and J. Arockiaraj, *Fish Physiol. Biochem.*, 2021, **47**, 1073–
915 1085.
- 916 69 K. M. Mohamed, M. S. Abdelfattah, M. El-khadragy, W. A. Al-Megrin, A. Fehaid, R.
917 B. Kassab and A. E. Abdel Moneim, *Green Process. Synth.*, , DOI:10.1515/gps-2023-
918 0010.
- 919 70 L. Tian, B. Lin, L. Wu, K. Li, H. Liu, J. Yan, X. Liu and Z. Xi, *Sci. Rep.*, 2015, **5**,
920 16117.
- 921 71 M. Rima, Y. Lattouf, M. Abi Younes, E. Bullier, P. Legendre, J.-M. Mangin and E.
922 Hong, *Sci. Rep.*, 2020, **10**, 15338.
- 923 72 F. Li, J. Lin, X. Liu, W. Li, Y. Ding, Y. Zhang, S. Zhou, N. Guo and Q. Li, *Ann.*
924 *Transl. Med.*, 2018, **6**, 173–173.
- 925 73 U. Kristan, P. Planinšek, L. Benedik, I. Falnoga and V. Stibilj, *Chemosphere*, 2015,
926 **119**, 231–241.
- 927 74 T. Nie, H. Wu, K. H. Wong and T. Chen, *J. Mater. Chem. B*, 2016, **4**, 2351–2358.
- 928 75 J. Machat, V. Otruba and V. Kanicky, *J. Anal. At. Spectrom.*, 2002, **17**, 1096–1102.
- 929 76 C. Ramamurthy, K. S. Sampath, P. Arunkumar, M. S. Kumar, V. Sujatha, K.
930 Premkumar and C. Thirunavukkarasu, *Bioprocess Biosyst. Eng.*, 2013, **36**, 1131–1139.
- 931 77 P. K. Issac and K. Velumani, *Bionanoscience*, , DOI:10.1007/s12668-024-01430-z.
- 932 78 N. S. Dumore and M. Mukhopadhyay, *J. Mol. Struct.*, 2020, **1205**, 127637.
- 933 79 A. J. Kora, *IET nanobiotechnology*, 2018, **12**, 658–662.
- 934 80 S. Y. Williams and B. J. Renquist, *J. Vis. Exp.*, , DOI:10.3791/53297.
- 935 81 F. Gao, Z. Yuan, L. Zhang, Y. Peng, K. Qian and M. Zheng, *Nanomaterials*, 2023, **13**,



- 936 2629.
- 937 82 K. Kalishwaralal, S. Jeyabharathi, K. Sundar and A. Muthukumaran, *Artif. Cells,*
938 *Nanomedicine, Biotechnol.*, 2015, 1–7.
- 939 83 Y. Wang, J. Tian, F. Shi, X. Li, Z. Hu and J. Chu, *Microbiol. Immunol.*, 2021, **65**,
940 410–421.
- 941 84 P. K. Issac, A. Guru, M. Velayutham, R. Pachaiappan, M. V. Arasu, N. A. Al-Dhabi,
942 K. C. Choi, R. Harikrishnan and J. Arockiaraj, *Life Sci.*, 2021, **283**, 119864.
- 943 85 C. Lite, A. Guru, M. Juliet and J. Arockiaraj, *Environ. Toxicol.*, 2022, **37**, 1988–2004.
- 944 86 M. M. Bradford, *Anal. Biochem.*, 1976, **72**, 248–54.
- 945 87 M. Velayutham, B. Ojha, P. K. Issac, C. Lite, A. Guru, M. Pasupuleti, M. V. Arasu, N.
946 A. Al-Dhabi and J. Arockiaraj, *Cell Biol. Int.*, 2021, **45**, 2331–2346.
- 947 88 P. K. Issac, J. J. Santhi, V. A. Janarthanam and K. Velumani, *Bionanoscience*, ,
948 DOI:10.1007/s12668-024-01383-3.
- 949 89 K. Schulz, S. Kerber and M. Kelm, *Nitric Oxide*, 1999, **3**, 225–234.
- 950 90 M. Krishnan and S. C. Kang, *Neurotoxicol. Teratol.*, 2019, **74**, 106811.
- 951 91 O. Yamanaka and R. Takeuchi, *J. Exp. Biol.*, , DOI:10.1242/jeb.182469.
- 952 92 G. Sudhakaran, A. Chandran, A. R. Sreekutty, S. Madesh, R. Pachaiappan, B. O.
953 Almutairi, S. Arokiyaraj, Z. A. Kari, G. Tellez-Isaias, A. Guru and J. Arockiaraj,
954 *Molecules*, 2023, **28**, 5350.
- 955 93 N. Qamar, P. John and A. Bhatti, *Int. J. Nanomedicine*, 2020, **Volume 15**, 3497–3509.
- 956



Table 1 Primer sequence used in RT-PCR

Gene	Forward Primer(5' to 3')	Reverse Primer (5' to 3')	Reference
SOD	GGTCCGCACTTCAACCCTCA	TACCCAGGTCTCCGACGTGT	NCBI: NM_131294.1
CAT	AACTGTGGAAGGAGGGTCGC	CGCTCTCGGTCAAAATGGGC	NCBI: XM_021470442.1
GSR	GATGGGCACCATAGCTAACCC	CATGAGCAGGAAGCAACACCC	NCBI: XM_005169592.4
GPx	AACTACACTCAGCTTGCGGC	TCCGCTTCACTTCCAGGCTC	NCBI: NM_001030070.2
β -actin	AAGCTGTGACCCACCTCACG	GGCTTTGCACATACCGGAGC	NCBI: NM_131031.2

